Guiding indication expansion with multimodal real-world data

Discover how a biopharma company used Tempus’ multimodal real-world data to guide its indication expansion strategy. See how our analysis of biomarker prevalence helped them identify new opportunities, prioritize R&D, and inform future trial design.